drugset / Trial / NCT01387711

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

NCT01387711

Phase 1 Completed 27 enrolled LEO Pharma
NaSingle-groupOpen-labelOther

Summary

This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by histology.

Timeline

Start
2011-08
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ingenol mebutate Small molecule 0.05 % Topical

Indications